Skip to main content

FDA Updates

FDA Updates, Bladder Cancer

Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Breast Cancer

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Loretta Fala, Medical Writer

FDA Updates, Leukemia

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates, Lymphoma

Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma

Loretta Fala, Medical Writer

FDA Updates, Ovarian Cancer

Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

FDA Updates

The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers

Peter R. Fendt, PharmD, MBA, Brian Ung, PharmD, RPh, F. Randy Vogenberg, RPh, PhD

FDA Updates

Welcome to the Second Annual Oncology Pharmacy Guide to New FDA Approvals

Novel Pharmaceuticals, FDA Updates

FDA Approvals of Brand-Name Prescription Drugs in 2016

Drug Profiles/Updates, FDA Updates

Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma

Loretta Fala, Medical Writer

1
2
3
4
5
6
7

Page 4 of 7
Results 31 - 40 of 66